Write what you believe about your stocks; every morning the cited record grades it: supported, challenged, or untouched. Never opinions.

Development · 5 Nov 2026

SUNPHARMA, full dossier

Sun Pharmaceutical Industries Ltd reported a Net Profit of ₹1,995.07 crore, a 36.16 per cent year-on-year decline.

7 publishers have reported this development. Each act of reporting is below, cited.

The record

Sun Pharmaceutical Industries Ltd reported a Net Profit of ₹1,995.07 crore, a 36.16 per cent year-on-year decline.

Sun Pharmaceutical Industries reported a 36.36 percent decline in consolidated net profit to Rs 1,988.53 crore for the September quarter.

Sun Pharmaceutical Industries reported 11.8% year-on-year growth in sales to ₹16,100 crore in Q2 FY27. Adjusted net profit stood at ₹3,162 crore, while reported net profit was ₹1,988.5 crore. EBITDA increased 4.8% to ₹4,743.9 crore, with an EBITDA margin of 29.3%.

Sun Pharmaceutical Industries reported a consolidated net profit of ₹1,988.53 crore for the July-September quarter, a 36.36% year-on-year decline from ₹3,124.95 crore in the same period last year.

livemint.com1 Nov 2026

Sun Pharma's net profit fell 36.2% to Rs 1,988.53 crore in the quarter ended September 2026, impacted by a one-time loss of Rs 1,269 crore.

ndtvprofit.com30 Oct 2026

Sun Pharmaceutical Industries reported a 36 per cent year-on-year decline in consolidated net profit to ₹1,988.5 crore for the second quarter of 2026-27, weighed down by exceptional charges.

Sun Pharmaceutical Industries posted 11.8 per cent year-on-year growth in operating revenues to Rs 16,100 crore in the second quarter ended September this year.

indiatimes.com30 Oct 2026

Sun Pharmaceutical Industries consolidated net profit declined 36.22% to Rs 1988.53 crore in the quarter ended September 2026.

Sun Pharma reported a 36.22 per cent year-on-year decline in consolidated net profit for the September quarter (Q2 FY27), with net profit standing at Rs 1,988.53 crore compared to Rs 3,117.95 crore in the corresponding quarter last year.

businesstoday.in30 Oct 2026

New here? The reader's guide explains every page, plate by plate.

fregime is informational research software. Content on this page is factual reporting compiled from cited public sources; nothing here is advice, and nothing here expresses an opinion on any security. fregime is not registered with SEBI as an investment adviser or research analyst. Before making investment decisions, consult a SEBI-registered adviser. Price figures are delayed end-of-day values cited to the exchange's published file, never live quotes.